Next report date
Report period
Q1 2024
EPS estimate
−2.17USD
Revenue estimate
—
−17.11USD
−35.81 MUSD
3.41 M
About eFFECTOR Therapeutics, Inc.
Sector
Industry
CEO
Stephen T. Worland
Website
Headquarters
Solana Beach
Employees (FY)
14
Founded
2012
FIGI
BBG00YMWT4N5
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EFTR is 1.80 USD — it has decreased by 2.70% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange eFFECTOR Therapeutics, Inc. stocks are traded under the ticker EFTR.
eFFECTOR Therapeutics, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
EFTR stock is 3.86% volatile and has beta coefficient of 2.34. Check out the list of the most volatile stocks — is eFFECTOR Therapeutics, Inc. there?
EFTR earnings for the last quarter are −3.25 USD per share, whereas the estimation was −3.08 USD resulting in a −5.41% surprise. The estimated earnings for the next quarter are −2.82 USD per share. See more details about eFFECTOR Therapeutics, Inc. earnings.
eFFECTOR Therapeutics, Inc. revenue for the last quarter amounts to 867.00 K USD despite the estimated figure of 802.75 K USD. In the next quarter revenue is expected to reach 664.40 K USD.
Yes, you can track eFFECTOR Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
EFTR stock has fallen by 5.76% compared to the previous week, the month change is a 85.35% fall, over the last year eFFECTOR Therapeutics, Inc. has showed a 81.87% decrease.
EFTR net income for the last quarter is −9.13 M USD, while the quarter before that showed −8.30 M USD of net income which accounts for −9.95% change. Track more eFFECTOR Therapeutics, Inc. financial stats to get the full picture.
Today eFFECTOR Therapeutics, Inc. has the market capitalization of 6.82 M, it has decreased by 10.55% over the last week.
No, EFTR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EFTR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade eFFECTOR Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 14.00 employees. See our rating of the largest employees — is eFFECTOR Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So eFFECTOR Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating eFFECTOR Therapeutics, Inc. stock shows the sell signal. See more of eFFECTOR Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on eFFECTOR Therapeutics, Inc. future price: according to them, EFTR price has a max estimate of 175.00 USD and a min estimate of 10.00 USD. Read a more detailed eFFECTOR Therapeutics, Inc. forecast: see what analysts think of eFFECTOR Therapeutics, Inc. and suggest that you do with its stocks.